Cellectis S.A. (ALCLS.PA)
Develops gene-edited immune cells to treat blood cancers and solid tumors.
2.51-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+1.0%
The outlook
Cellectis trades well below its 50- and 200-day moving averages and sits near the lower end of its 52-week range, reflecting weakness in recent momentum. Analysts have a notably bullish average target around 159% above the current price, though overall sentiment leans bearish. The disconnect between the weak technical position and optimistic price targets suggests divergent views on the company's near-term versus longer-term prospects.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +159% vs current price
Market cap
$253.2M
52-wk high
4.84
52-wk low
2.03
50-day avg
2.71
200-day avg
3.28
Trailing P/E
—